Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2004 | 12-2003 | 12-2002 | 12-2001 | 12-2000 | |
| Sales | 26,284 | 29,489 | 25,610 | 22,559 | 22,048 |
| Cost of Goods | 8,576 | 11,227 | 9,718 | 8,241 | 11,098 |
| Gross Profit | 17,708 | 18,262 | 15,892 | 14,318 | 10,950 |
| Operating Expenses | 21,877 | 21,035 | 18,465 | 17,493 | 19,249 |
| Operating Income | -3,593 | -2,546 | -1,855 | -2,934 | -8,201 |
| Interest Expense | 152 | 238 | 511 | 846 | 1,131 |
| Other Income | 323 | 110 | 6 | 39 | 191 |
| Pre-tax Income | -3,422 | -2,674 | -2,360 | -3,741 | -9,141 |
| Income Tax | 93 | 47 | 41 | N/A | N/A |
| Net Income Continuous | -3,515 | -2,711 | -2,189 | -3,656 | -9,141 |
| Net Income Discontinuous | -1,464 | N/A | N/A | N/A | N/A |
| Net Income | $-4,979 | $-2,711 | $-2,189 | $-3,656 | $-9,589 |
| EPS Basic Total Ops | -2,698.65 | -1,799.10 | -1,799.10 | -2,998.50 | -8,695.65 |
| EPS Basic Continuous Ops | -1,799.10 | -1,788.70 | -1,679.52 | -2,982.59 | -8,395.80 |
| EPS Basic Discontinuous Ops | -899.55 | N/A | N/A | N/A | N/A |
| EPS Diluted Total Ops | -2,698.65 | -1,799.10 | -1,799.10 | -2,998.50 | -8,695.65 |
| EPS Diluted Continuous Ops | -1,799.10 | -1,788.70 | -1,679.52 | -2,982.59 | -8,395.80 |
| EPS Diluted Discontinuous Ops | -899.55 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-152 | $1,351 | $3,070 | $2,074 | $-1,905 |